Search clinical trials for: Trastuzumab plus Pertuzumab

Total 6121 results

Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
European Organisation for Research and Treatment...
Hoffmann-La Roche

Completed

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Elderly Metastatic Breast Cancer Population

Belgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini

China
Shengjing Hospital

Not yet recruiting

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Breast Cancer

China
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Breast Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Roche Pharma AG

Completed

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (TRAP)

Esophageal Carcinoma

Netherlands
Hospices Civils de Lyon

Not yet recruiting

PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study (PETRA)

HER-2 Positive Breast Cancer

France
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Fujian Medical University Union Hospital

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Breast Cancer | Adjuvant Therapy

China
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer

China
Genentech, Inc.

Approved for marketing

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

HER2-positive Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Breast Cancer Metastases | HER2 Positive Breast

United States
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Breast Cancer

United States
Fundacio Clinic Barcelona
Roche Pharma AG; SOLTI Breast Cancer Research Group

Recruiting

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (ELPIS)

Stage I Breast Cancer | HER2-positive Breast Cancer

Spain
Hoffmann-La Roche

Completed

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Healthy Male Subjects

Australia, New Zealand
Peking University Cancer Hospital & Institute

Recruiting

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab (HELP)

HER2-positive Metastatic Breast Cancer | Previously Treated With Trastuzumab | Trastuzumab Combined With Pertuzumab and Chemotherapy

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Unknown

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Breast Cancer

China
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Ulrik Lassen
GlaxoSmithKline; Pfizer; Roche Pharma AG

Recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)

Neoplasms | Cancer | Tumors | Neoplasia

Denmark
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer (PREDIX HER2)

Early-Stage Breast Carcinoma | HER-2 Positive Breast Cancer

Sweden
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Institut für Klinische Krebsforschung IKF GmbH...
Trium Analysis Online GmbH

Completed

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (PETRARCA)

Stomach Cancer | Gastroesophageal Junction Cancer

Germany
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Metastatic Breast Cancer
Nancy Lin, MD
Genentech, Inc.

Active, not recruiting

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

HER2-positive Metastatic Breast Cancer | Central Nervous System Metastases

United States
Peking University People's Hospital

Recruiting

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

HER2-positive Early Breast Cancer

China
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Breast Cancer

United States, Italy, United Kingdom, Australia, Austria, Belgium, Brazil, Denmark, France, Guatemala, Korea, Republic of, Portugal, Spain, Turkey, Colombia, Canada, Czechia, Japan, Poland, Romania, Russian Federation, Switzerland, ... and more
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer

France, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
NSABP Foundation Inc
Washington University School of Medicine; Breast Cancer Research Foundation

Active, not recruiting

NSABP Biospecimen Discovery Project

Breast Cancer

United States
Hoffmann-La Roche

Completed

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Breast Cancer

Hungary, Italy, Spain, France, United Kingdom, Belgium, Germany, Portugal, Poland, Canada, Bulgaria, Mexico
Queen Mary University of London
Gilead Sciences

Unknown

Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

United Kingdom
Tianjin Medical University Cancer Institute and...
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer (Pyramid)

HER2+ Early or Locally Advanced Breast Cancer
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
University of Michigan Rogel Cancer Center

Completed

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Breast Cancer

United States
Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Cancer

China
Institut Català d'Oncologia
Fundación Sociedad Española de Oncologia Médica; Instituto de Salud Carlos III and other collaborators

Recruiting

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)

Neoplasms | Breast Cancer | HER2-positive Breast Cancer

Spain
Fondazione del Piemonte per l'Oncologia

Unknown

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer (HERACLES)

Metastatic Colorectal Cancer

Italy
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE)

Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Gallbladder Neoplasms | Prostatic Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Haematological Malignancy | Urinary Bladder Neoplasm | Skin Neoplasm | Salivary Gland Neoplasm

United Kingdom
Hoffmann-La Roche

Completed

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Breast Cancer

Canada, Spain, France, United Kingdom, Italy
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Genentech, Inc.

Completed

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis

United States
Helsinki University Central Hospital

Active, not recruiting

Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (BOLD-1)

Breast Cancer

Finland
Genentech, Inc.

Completed

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer

Search clinical trials for: Trastuzumab plus Pertuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations